Shanghai Juncell Therapeutics Co., a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, has announced the grand opening of its state-of-the-art TIL manufacturing facility located at Anting International Medical Industry Park in Jiading District, Shanghai, China. This facility has the largest capacity and was constructed in compliance with the highest standards.

Juncell Therapeutics' state-of-the-art facility, with a total area exceeding 16,000 square meters, houses the company's production centre, quality centre, data and operation centre.

This facility, with a designed production capacity of TIL products for 6,000-10,000 patients annually, represents another significant milestone following the approval of GC101, the world's first IL-2-administration-free natural TIL therapy with a low-intensity pretreatment, to enter the pivotal Phase II clinical trial.

The establishment of this facility will significantly promote the development of high-quality TIL products and the transformation of disruptive technologies into new quality productive forces.

Officials from National Development and Reform Commission, Shanghai Municipality, Jiading District, Anting Town, and Anting International Medical Industry Park, as well as representatives from various investment institutions, clinical experts, and executives from leading industrial companies, attended the ceremony to witness the grand opening of Juncell's high-standard TIL manufacturing facility, and to celebrate Juncell's development milestone.

Zhou Hanmin, a Standing Committee Member of the CPPCC National Committee and Chairman of Shanghai Public Diplomacy Association, believes that the launch of Juncell Therapeutics' state-of-the-art TIL manufacturing facility will strongly promote the development of the TIL therapy industry, benefit cancer patients and create huge social and economic values.